The estimated Net Worth of Donald Abbey is at least $23.5 Milion dollars as of 15 May 2024. Mr. Abbey owns over 948 units of Dexcom Inc stock worth over $207,259 and over the last 8 years he sold DXCM stock worth over $20,346,229. In addition, he makes $2,919,160 as Executive Vice President - Quality and Regulatory Affairs at Dexcom Inc.
Sign up
Mr. Abbey DXCM stock SEC Form 4 insiders trading
Donald has made over 17 trades of the Dexcom Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 948 units of DXCM stock worth $64,910 on 15 May 2024.
The largest trade he's ever made was selling 11,604 units of Dexcom Inc stock on 21 November 2019 worth over $2,555,317. On average, Donald trades about 2,637 units every 65 days since 2016. As of 15 May 2024 he still owns at least 3,027 units of Dexcom Inc stock.
You can see the complete history of Mr. Abbey stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Donald Abbey biography
Donald M. Abbey serves as Executive Vice President - Quality and Regulatory Affairs of the Company. He has served as our Executive Vice President, Quality and Regulatory Affairs since January 2017 and served as our Executive Vice President, Quality from May 2016 to January 2017. From March 2007 to April 2016 , Mr. Abbey served in executive roles for Becton Dickinson (the acquirer of CareFusion in March 2015 which itself was spun off from Cardinal Health in 2009), including as Senior Vice President, Quality and Regulatory for Becton Dickinson from March 2015 to May 2016, as Executive Vice President, Quality, Regulatory and Medical Affairs for CareFusion from May 2011 to March 2015, as Senior Vice President, Quality and Regulatory for CareFusion from October 2009 to May 2011, and as Senior Vice President, Quality and Regulatory for Cardinal Health from March 2007 to October 2009. Prior to 2007 Mr. Abbey held senior quality and regulatory affairs and general management positions with Respironics, Welch Allyn, and Philips Healthcare. Mr. Abbey began his career at Varian Medical and Boston Scientific holding positions of increasing responsibility in research and development and quality. Mr. Abbey received a B.S.E.E. from Washington State University and an M.B.A. from the University of Washington.
What is the salary of Donald Abbey?
As the Executive Vice President - Quality and Regulatory Affairs of Dexcom Inc, the total compensation of Donald Abbey at Dexcom Inc is $2,919,160. There are 5 executives at Dexcom Inc getting paid more, with Kevin Sayer having the highest compensation of $10,279,400.
How old is Donald Abbey?
Donald Abbey is 53, he's been the Executive Vice President - Quality and Regulatory Affairs of Dexcom Inc since 2017. There are 18 older and 11 younger executives at Dexcom Inc. The oldest executive at Dexcom Inc is Andrew K. Balo, 73, who is the Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel..
What's Donald Abbey's mailing address?
Donald's mailing address filed with the SEC is 951, Calle Amanecer, San Clemente, Orange County, California, 92673, United States.
Insiders trading at Dexcom Inc
Over the last 20 years, insiders at Dexcom Inc have traded over $724,717,982 worth of Dexcom Inc stock and bought 165,450 units worth $3,489,100 . The most active insiders traders include Sean Carney, Kim D Blickenstaff oraz Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of $892,438. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth $29,458.
What does Dexcom Inc do?
founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.
What does Dexcom Inc's logo look like?
Complete history of Mr. Abbey stock trades at Dexcom Inc i ICU Medical
Dexcom Inc executives and stock owners
Dexcom Inc executives and other stock owners filed with the SEC include:
-
Kevin Sayer,
Chairman of the Board, President, Chief Executive Officer -
Quentin Blackford,
Chief Financial Officer, Chief Operating Officer -
Richard Doubleday,
Executive Vice President, Chief Commercial Officer -
Andrew Balo,
Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development -
Steven Pacelli,
Executive Vice President - Strategy and Corporate Development -
Donald Abbey,
Executive Vice President - Quality and Regulatory Affairs -
Kevin Ronald Sayer,
Exec. Chairman, CEO & Pres -
Jacob Steven Leach,
Exec. VP & CTO -
Bridgette Heller,
Independent Director -
Mark Foletta,
Lead Independent Director -
Eric Topol,
Independent Director -
Jay Skyler,
Independent Director -
Nicholas Augustinos,
Independent Director -
Steven Altman,
Independent Director -
Barbara Kahn,
Independent Director -
Richard Collins,
Independent Director -
Kyle Malady,
Independent Director -
Karen Dahut,
Independent Director -
Shelly Selvaraj,
Senior Vice President - Information Technology -
Jeffrey Moy,
Senior Vice President - Operations -
Jereme Sylvain,
Senior Vice President - Finance, Chief Accounting Officer -
Patrick Murphy,
Executive Vice President, Chief Legal Officer -
Jake Leach,
Executive Vice President, Chief Technology Officer -
Shelly Ramasamy Selvaraj,
Sr. VP of Information Technology -
Donald M. Abbey,
Exec. VP of Global Bus. Services, IT, Quality & Regulatory Affairs -
Steven R. Pacelli,
Exec. VP & MD of Dexcom Ventures -
Andrew K. Balo,
Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel. -
Sadie M. Stern,
Exec. VP & Chief HR Officer -
Chad M. Patterson,
Exec. VP of Global Marketing -
Sean Christensen,
Director of Corp. Affairs & Head of Investor Relations -
Jereme M. Sylvain,
Exec. VP, CFO & Chief Accounting Officer -
John Lister,
VP, Legal Affairs -
Terrance H Gregg,
Director -
Jess Roper,
VP, CFO -
Jorge A Valdes,
Vice President of Engineering -
Girish Naganathan,
EVP Chief Technology Officer -
Heather S Ace,
SVP Human Resources -
Kevin M Sun,
VP, Corp Controller & Treasury -
Jonathan T Md Lord,
Director -
Glen D Nelson,
Director -
Peter Gerhardsson,
VP, Int'l Business Development -
David Carner,
VP, Quality Assurance -
Laura Johnson,
V.P., Intellectual Property -
Martin Doordan,
Director -
Sean Carney,
Director -
John Riolo,
VP of Quality Assurance -
Claudia Graham,
VP, Marketing -
Donald A Lucas,
Director -
Donald L Lucas,
Director -
Mark Brister,
VP, Advanced Development Teams -
Richard Yang,
V.P., Strategic Affairs -
James H Brauker,
VP, Research & Development -
Rodney L Kellogg,
Vice President of Sales -
Andrew P Rasdal,
President and CEO -
Steven J Kemper,
Chief Financial Officer -
Kim D Blickenstaff,
Director -
Tae Andrews,
Vice President of Marketing -
Paul Travelers Companies In...,
-
Pincus Private Equity Viii ...,
-
Brenton Karl Ahrens,
Director -
Nancy Sfog City Management ...,
-
Equity Partners Ii Llccanaa...,
-
Paul Travelers Companies In...,
-
Eric A Charmers Landing Llc...,
-
Scott Lwindamere Llcwindame...,
-
Equity Partners Ii Llc Waub...,
-
Teri L Lawver,
EVP Chief Commercial Officer -
Paul R Flynn,
EVP Global Revenue -
Matthew Vincent Dolan,
EVP Strategy and Corporate Dev -
Sumi Shrishrimal,
SVP Chief Risk Officer -
Chad Patterson,
EVP Global Marketing -
Barry J. Regan,
EVP Operations -
Jacob Steven Leach,
EVP, Chief Operating Officer -
Rimma Driscoll,
Director -
Michael Jon Brown,
EVP, Chief Legal Officer -
Sadie Stern,
EVP, Chief HR Officer